Author:
Bender Brendan C.,Schaedeli-Stark Franziska,Koch Reinhold,Joshi Amita,Chu Yu-Waye,Rugo Hope,Krop Ian E.,Girish Sandhya,Friberg Lena E.,Gupta Manish
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference24 articles.
1. Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–9290. doi: 10.1158/0008-5472.CAN-08-1776
2. Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698–2704. doi: 10.1200/JCO.2009.26.2071
3. Burris HA III, Rugo H, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405. doi: 10.1200/JCO.2010.29.5865
4. Krop I, LoRusso P, Miller KD et al (2010) A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at European Society for Medical Oncology Congress, October 8–12, Milan, Italy (abstract 277O)
5. Gupta M, LoRusso PM, Wang B et al (2011) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. doi: 10.1177/0091270011403742
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献